Last reviewed · How we verify
NCT07396337
Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
Phase 2 trial testing QHRD106 Injection (Low-dose group) in Acute Ischemic Stroke in 320 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Changzhou Qianhong Bio-pharma Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 320 |
| Start date | 19 January 2026 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- QHRD106 Injection (Low-dose group) — full drug profile →
- QHRD106 Injection (Middle-dose group) — full drug profile →
- QHRD106 Injection (High-dose group) — full drug profile →
- Placebo
Conditions studied
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Changzhou Qianhong Bio-pharma Co., Ltd. — full company profile →
Who can join
Adults 18 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07396337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Ischemic Stroke
Currently open trials in the same condition.
- NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
- NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
- NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting
Other Changzhou Qianhong Bio-pharma Co., Ltd. trials
Trials by the same sponsor.
- NCT06532058 — Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia · Phase 2 · recruiting
- NCT06380699 — Study to Assess PK, Safety and Tolerability in Healthy Subjects · Phase 1 · completed
- NCT06388772 — Study to Assess PK, Safety and Tolerability Early in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07396337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changzhou Qianhong Bio-pharma Co., Ltd.
- Last refreshed: 9 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07396337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing